Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2006, Pages

  Granger, R ^b   Walters, J ^b   Poole, P J ^b   Lasserson, T J ^b   Mangtani, P ^b   Cates, C J ^b   Wood Baker, Richard ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PLACEBO; PNEUMO23; PNEUMOCOCCUS VACCINE; PREDNISOLONE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; BACTERIAL PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EMERGENCY TREATMENT; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; LUNG FUNCTION; MORTALITY; PNEUMONIA; QUALITY CONTROL; REVIEW; SEPSIS; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS INFECTION; TREATMENT OUTCOME; VACCINATION;

EID: 34548864985     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001390.pub2     Document Type: Review

References (95)

1. Alfageme I, Reyes N, Vazquez R, Perez J, Munoz, Hernandez M, et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest 2004;126(4 Suppl):837S.
2. * Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006;61:189-95.
3. Davis AL, Aranda CP, Schiffman G, Christianson LC. [Pneumoccoccal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary desease. A pilot study]. Chest 1987; 92(2):204-12.
4. Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. CMAJ 1987;136(4): 361-5.
5. * Steentoft J, Konradsen HB, Hilskov J, Giglason G, Andersen JR. Response to pneumococcal vaccine in chronic obstructive lung disease - the effect of ongoing, systemic steroid treatment. Vaccine 2006; 24:1408-12.
6. Aboussouan LS. Acute exacerbations of chronic bronchitis: Focusing management for optimum results. Postgraduate Medicine 1996;99 (4):89-104.
7. Anonymous. Pneumococcal vaccines: World Health Organization position paper. Weekly Epidemiological Record 1999;74(23):177-83.
8. Anonymous. Pneumococcal vaccines: World Health Organization position paper. Canada Communicable Disease Report 1999;25(17): 150-1.
9. Austrian R, Douglas RM, Schiffman C. Prevention of pneumococcal pneumonia by vaccination. Transactions of the Association of American Physicians 1976;89:184-94.
10. Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Reviews of Infectious Diseases 1981;3(Suppl):S1-S17.
11. Austrian R. A reassessment of pneumococcal vaccine. New England Journal of Medicine 1984;310:651-3.
12. Bacle A, Diot P, Lemarie E. Anti-pneumococci vaccine: justifications and results. Revue de Pneumologie Clinique 1997;53(3):128-37.
13. Bentley DW. Pneumococcal vaccine in the institutionalized elderly: review of past and recent studies. Reviews of Infectious Diseases 1981; 3(Suppl):S61-S70.
14. Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW, Schlech WF. Pneumococcal vaccine efficacy in selected populations in the United States. Annals of Internal Medicine 1986;104:1-6.
15. Broome CV. Efficacy of pneumoncoccal polysaccharide vaccines. Reviews of Infectious Diseases 1981;3(Suppl):S82-S88.
16. Butler JC, Breiman RF, Campbell JF, et al. Efficacy of the pneumoncoccal vaccine: Is once enough?. Interscience Conference of Antimicrobial Agents and Chemotherapy, Anaheim, CA. 1992.
17. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome C, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. JAMA 1993; 270:1826-31.
18. Chodosh S. Treatment of acute exacerbations of chronic bronchitis: state of the art. The American Journal of Medicine 1991;91(Suppl 6A):87S-91S.
19. Christenson B, Lundbergh P, Hedlund J, Ortqvist A. [Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years of older: a prospective study]. Lancet 2001;357(9261):1008-11.
20. * Davies AL. Effects of 14-valent pneumococcal polysaccharide vaccine in patients with COPD. Chest 1984;85(Suppl):582-3.
21. Douglas RM, Riley ID. Pneumococcal disease and its prevention with plyvalent pneumococcal polysaccharide vaccines- a review. Australian and New Zealand Journal of Medicine 1979;9(327-38).
22. Douglas RM, Miles HB. Vaccination against streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children. The Journal of Infectious Diseases 1984;149(6):861-9.
23. Ekwurzel GM, Simmons JS, Dublin LI, Felton LD. Studies on immunizing substances in pneumococci. Public Health Reports 1938; 53:1877-93.
24. Ewig S, Soler N, Torres A. Chronic obstructive pulmonary disease and infection: fromstable patients to pneumonia. Clinical Pulmonary Medicine 1999;6(1):1-8.
25. Farr BM, Johnston BL, Cobb DK, et al. Preventing pneumoncoccal bacteremia in patients at risk. Archives of Internal Medicine 1995;155: 2336-40.
26. Fedson D, Henrichsen J, Makela H, Austrian R. Immunization of elderly people with polyvalent pneumococcal vaccine. Infection 1989; 617(6):437-41.
27. Fedson DS, Shapiro ED, LaForce FM, Mufson MA, Musher DM, Spika JS, et al. Pneumococcal vaccine after 15 years of use. Another view. Archives of Internal Medicine 1994;154(22):2531-5.
28. Fedson DS. The clinical effectiveness of pneumococcal vaccination: a brief review. Vaccine 1999;17:S85-S90.
29. Felton LD, Ekwurtzel GM, Simmons JS, Dublin LI. Public Health Reports 1938;53:1877.
30. Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. New England Journal of Medicine 1993;328(17): 1017-22.
31. Filice GA. Pneumoccal vaccines and public health policy. Archives of Internal Medicine 1990;150:1373-5.
32. Fine MJ, Smith MA, Carson CA, Meffe F, Snakey SS, Weissfeld LA, et al. Efficacy of pneumococcal vaccination in adults. Ameta-analysis of randomized controlled trials. Archives of Internal Medicine 1994; 154(23):2666-77.
33. Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high-risk population. The American Journal of Medicine 1987;83(3):425-30.
34. Foschino BMP, Resta O, Cassano A, Altieri A, Guido P, Piti A, et al. Infectious exacerbations of chronic pulmonary diseases. Therapeutic effectiveness of immunomodulants [Riacutizzazioni delle broncopneumopatie croniche]. Minerva Pneumologica 1995;43(2):39-44.
35. Gable CB, Holzer SS, Engelhart L, Friedman RB, Smeltz F, Schroeder D, et al. Pneumococcal vaccine: efficacy and associated cost savings. JAMA 1990;264:2910-5.
36. Gaillat J, Zmirou D, Mallaret MR, et al. Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions [Essai clinique du vaccin antipneumococcique chez des personnes agees vivant en institution]. Revue d'Epidemiologie et de Sante Publique 1985; 33(6):437-44.
37. Gardner P, Schaffner W. Immunization of adults. New England Journal of Medicine 1993;328(17):1252-8.
38. Hak E, van Essen GA, Buskens E, Stalman W, de Melker RA. Is immunising all patients with chronic lung desease in the community against influenza cost effective? Evidence from a general practice gased clinical prospective cohort study in Utrecht, The Netherlands. Journal of Epidemiology and Community Health 1998;52(2):120-5.
39. Halasa J, Halasa M, Wojciechowska W, Podkowinska I, Kucharska E. Clinical efficacy of autovaccine in the treatment of infectious nonatopic asthma and COPD- double blind placebo controlled trial [Ocena efektow leczenia autoszczepionka astmy nieatopowej infekcyjnej i POChP - badanie z zastosowaniem podwojnie slepej proby z placebo]. Alergia Astma Immunologia 2001;6(2):109-13.
40. Hilleman MR, Carlson AJJr, McLean AA, Vella PP, Weibel RE, Woodhour AF. Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination , and simultaneous administration of pneumococcal and influenza vaccines. Reviews of Infectious Diseases 1981;3(Suppl):S31-S42.
41. Hirschmann JV, Lipsky BA. Pneumococcal vaccine in the United States: a critical analysis. JAMA 1981;246:1428-32.
42. Hirschmann JF. The pneumococcal vaccine after 15 years of use. Archives of Internal Medicine 1994;154:373-7.
43. * Horwood F, Macfarlane J. Pneumococcal and influenza vaccination: current situation and future prospects. Thorax 2002;57(Suppl II): ii24-ii30.
44. * Jackson L, Neuzil K, Yu O, Benson P, Barlow W, Adams A, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. New England Journal of Medicine 2003;348(18):1747-55.
45. Jonsson S, Vidarsson G, Valdimarsson H, Schiffman G, Schneerson R, Jonsdottir I. Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine. European Respiratory Journal 2002;20(4):813-8.
46. Kaiser AB, Schaffner W. Prospectus: the prevention of bacteremic pneumococcal pneumonia. A conservative appraisal of vaccine intervention. Journal of the American Medical Association 1974;230(3): 404-8.
47. * Kaufman P. Studies on old age pneumonia II. Prophylactic effect of pneumoncoccus polysaccharide against pneumonia. Archives of Internal Medicine 1941;67:304-19.
48. Kaufman P, Kaeffely A, Klingst SK, O'Brien C, Stein H. Pneumonia in old age: active immunization against pneumonia with pneumococcus polysaccharide: results of a six-year study. Archives of Internal Medicine 1947;79:518-31.
49. Klastersky J, Mommen P, Cantraine F, Safary A. Placebo controlled pneumococcal immunisation in patients with bronchogenic carcinoma. European Journal of Cancer and Clinical Oncology 1986;22: 807-13.
50. Klein RS, Adachi N. Pneumococcal vaccine in the hospital. Improved use and implications for high-risk patients. Archives of Internal Medicine 1983;143(10):1878-81.
51. Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococal vaccine in the elderly: A randomized, single-blind population-based trial. American Journal of Medine 1997;103:281-90.
52. * Kraus C, Fischer S, Ansorg R, Huttemann U. Pneumococcal antibodies (IgG, IgM) in patients wih chronic obstructive lung disease 3 years after pneumococcal vaccination. Medical Microbiology and Immunology 1985;174(1):51-8.
53. LaForce LM. Pneumococcal vaccine. Seminars in Respiratory Infections 1989;4(4):293-8.
54. Landesman SH, Smith PM, Schiffman G. Pneumococcal vaccine in elderly patients with COPD. Chest 1983;84:433-5.
55. Larsson L. Use of antibiotics, antioxidants, mucolytics and vaccines in the therapy of chronic obstructive pulmonary disease. European Respiratory Monograph 1998;3(7):163-8.
56. Leophonte P, Neukirch F. Anti-pneuococci vaccination: Role and indications in the prevention of community acquired infections of the lower respiratory tract. Medecine et Maladies Infectieuses 2001;31 (4):181-94.
57. MacLeod CM, Hodges RG, Heidelberger M, Bern Hard NG. Prevention of pneumococcal pneumonia by immunisation with specific capsular polysaccharide. The Journal of Experimental Medicine 1945; 82:445-65.
58. Madison JM, Irwin RS. Chronic obstructive pulmonary disease. Lancet 1998;352(9126):467-73.
59. Monso E. Vaccination and antioxidant therapy [Vacunacion y tratamiento antioxidante]. Archivos de Bronconeumologia 2003;39 (Suppl 3):31-3.
60. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Archives of Internal Medicine 1999; 159(20):2437-42.
61. Orcel B, Delclaux B, Baud M, Derenne JP. Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. European Respiratory Journal 1994;7(3):446-52.
62. Ortqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998;351(9100):399-403.
63. Patrick KM, Woolley FR. A cost-benefit analysis of immunisation of pneumococcal pneumonia. JAMA 1981;245:473-7.
64. Preheim L, Rytel M. Pneumococcal infection after vaccination. Lancet 1978; Vol. 2:1317.
65. Riley RD, Tarr PI, Andrews M. Immunisation with a polyvalent pneumococcal vaccine: reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet 1977;1:1338-41.
66. Rochemaure J, Lehert Ph, Sauvaget J, Robillard M, Betbeder-Matibet A. Reduction with an immunomodulator of the infection rate in chronic bronchitis [Reduction par un immunomodulateur de taux d'infections respiratoires dans la bronchite chronique].Revue de Pneumologie Clinique 1988;44(1):43- 7.
67. Saag KG, Doebbeling BN, Rohrer JE, Kolluri S, Peterson R, Hermann ME, et al. Variation in tertiary prevention and health service utilization among the elderly. The role of urban-rural residence and supplemental insurance. Medical Care 1998;36(7):965-76.
68. Schwartz JS. Pneumoncoccal vaccine: clinical efficacy and effectiveness. Annals of Internal Medicine 1982;96:208-20.
69. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Annals of Internal Medicine 1984;101: 325-30.
70. Shapiro ED. Pneumococcal vaccine failure. New England Journal of Medicine 1987;316(20):1272-3.
71. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margollis A, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. New England Journal of Medicine 1991;323:1453-60.
72. Sheikh A. Evidence-based problem solving. What is the efficacy of pneumococcal vaccination in people with asthma?. Asthma in General Practice 1999;7(2):21-2.
73. Simberkoff MS, Cross AP, Al-Ibrahim M, Baltch AL, Geiseler PJ, Nadler J, et al. Efficacy of pneumococcal vaccine in high risk-patients. Results of a Veterans Administration Cooperative Study. New England Journal of Medicine 1986;315(21):1318-27.
74. Simberkoff MS. Pneumococcal vaccine in the prevention of community-acquired pneumonia: a skeptical view of cost-effectiveness. Seminars in Respiratory Infections 1993;8(4):294-9.
75. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Annals of Internal Medicine 1988;108(5):653-7.
76. Sisk JE, Riegelman RK. Cost effectiveness of vaccination against pneumococcal pneumonia: an update. Annals of Internal Medicine 1986;104:79-86.
77. Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR. Protective efficacy of pneumoncoccal polysaccharide vaccines. JAMA 1977;238:2613-6.
78. van Amptin JMA, Bouter KP, Diepersloot RJA, Overbeek BP, Netten P, Erkelens DW. Pneumococcal bacteraemia: incidence, outcome and predisposing factors. European Journal of Internal Medicine 1998;9: 145-50.
79. Wencker M, Konietzko N. Alpha-1-protease inhibitor deficiency and pulmonary emphysema as viewed by pulmonary specialists in private practice [Alpha-1-Proeinaseninhibitor-Mangel und Lungenemphysemaus der Sicht des niedergelassenen Pneumologen]. Atemwegs-und Lungenkrankheiten 1999;25(2):89-95.
80. * Wenzel P, Craven R, Davies J, Hendley J, Hamory B, Gwaltney J. Field trial of an inactivated mycoplasma pneumoniae vaccine. Journal of Infectious Diseases 1976;134(6):571-6.
81. Wiebel RE, Vella PP, McLean AA. Studies in human subjects of polyvalent pneucoccal vaccines. Proceedings of the Society for Experimental Biology and Medicine 1977;156:144-50.
82. Willems JS, Sanders CR, Riddiough MA. Cost effectiveness of vaccination against pneumococcal pneumonia. New England Journal of Medicine 1980;303:553-9.
83. Williams JH, Moser KM. Pneumococcal vaccine and patients with chronic lung disease. Annals of Internal Medicine 1986;104(1):106-9.
84. Wright AE, Morgan WP, Colebrook L, Dodgson RW. Prophylactic inoculation against pneumococcus infections. Lancet 1914:87-95.
85. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 1995;152(5 Pt 2):S77-S121.
86. American Thoracic Society. Management of stable COPD: pharmacological therapy. http://www.thoracic.org/COPD/6/other_agents. asp (accessed February 2005).
87. Balter MS, et al. Recommendations on the management of chronic bronchitis. CMAJ 1994;151:5-23.
88. COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS Guidelines for the management of chronic obstructive pulmonary disease. Thorax 1997;52:S7-S15.
89. Chapman KR. Therapeutic algorithm for chronic obstructive pulmonary disease. The American Journal of Medicine 1991;91:17S-23S.
90. McKenzie DK, Frith PA, Burdon JG, Town GI. The COPDX Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease. Medical Journal of Australia 2003;178(Suppl):7S-39S.
91. Moher D, Jadad AR, Tugwell P. Assessing the quality of randomized controlled trials:current issues and future directions. International Journal of Technology Assessment in Health Care 1996;12:195-208.
92. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59(Suppl 1):1-232.
93. National Heart Lung and Blood Institute. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda: National Heart, Lung and Blood Institute; 2001. NIH Publication No 2701: 1-100.
94. National Institute of Clinical Excellence. COPD: National clinical guideline on managment of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59(Suppl 1): 181-272.
95. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. American Journal of Respiratory and Critical Care Medicine 2001;163(5):1047-8.